Final Thoughts on New Developments and Emerging Agents
Panelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.
Treatment Approaches for TP53-Mutated AML
Key opinion leaders in hematology oncology share insights into the challenges associated with treating patients with TP53-mutated AML and highlight the recent FDA breakthrough designation of eprenetapopt.
Evolving Treatment Approaches Pre- and Post-Transplant
Vinod Pullarkat, MD, leads a detailed discussion on evolving treatment approaches using MRD pretransplant, and panelists consider recent therapeutic advances for the post-transplant setting.
5-Year Follow-up Data on CPX-351 for AML
A panel of specialists in hematology oncology review the 5-year follow-up data on the use of CPX-351 for adults and pediatric patients with acute myeloid leukemia.
The Role of Allogeneic Stem Cell Transplant in AML
Dan Pollyea, MD, MS provides a high-level overview of the role of allogeneic stem cell transplant at first remission based on risk stratification, highlighting how to select patients for transplant.
Approaches to Managing Toxicity of Venetoclax
Courtney DiNardo, MD emphasizes the importance of understanding the risk of tumor lysis syndrome, monitoring for drug-drug interactions, and performing a bone marrow biopsy at the end of cycle 1 when treating AML with venetoclax.
The Role of Venetoclax for Treatment of AML
Renowned experts in hematology-oncology provide insight into the practical implications of treating acute myeloid leukemia with the current standard-of-care regimen using venetoclax.
Venetoclax Combination Therapy for IDH-mutated AML
Key opinion leader in the management of acute myeloid leukemia, Harry Erba, MD PhD, builds a conversation on the use of venetoclax as a part of combination therapy in patients with IDH mutations.
Combination Approaches Targeting FLT3 and IDH Mutations
Expert hematologist-oncologists share insights into clinical trials studying how to best combine or sequence FLT3 and IDH inhibitors in patients with both mutations.
Toxicities Associated With IDH Inhibitors
A panel of key opinion leaders in acute myeloid leukemia reflects on the importance of considering the toxicity profiles of IDH inhibitors and emphasizes the challenges of diagnosing differentiation syndrome.
The Role of IDH Inhibitors for Treatment of AML
Harry Erba, MD, PhD; Courtney DiNardo, MD; and Dan Pollyea, MD, MS, discuss the role of the IDH inhibitors ivosidenib and enasidenib as single-agent or combination therapy in patients with acute myeloid leukemia (AML).
Second-Generation FLT3 Inhibitors for Acute Myeloid Leukemia
A panel of thought leaders in AML examines single-agent and combination-based approaches using the second-generation FLT3 inhibitors gilteritinib, quizartinib, and crenolanib.
The Role of FLT3 Inhibitors for Treatment of AML
Experts in hematologic malignancies provide key insights into the use of FLT3 inhibitors and discuss whether it is possible to predict patients who may benefit from midostaurin + chemotherapy.
Molecular Testing Turnaround Time and Treatment Delay
Key opinion leaders in acute myeloid leukemia reflect on challenges associated with molecular testing by commenting on potential treatment delay from the long turnaround time (TAT) of next-generation sequencing.
Molecular Testing for Acute Myeloid Leukemia
Mark Levis, MD, PhD, leads a panel of experts in a discussion on factors to consider when ordering molecular testing for newly diagnosed and relapsed/refractory acute myeloid leukemia.
Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD
Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma
Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL
Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS
2 Clarke Drive Cranbury, NJ 08512